Detection and quantification of unmethylated circulating insulin (INS) DNA presumably released from b cells has been previously used for assessing their destruction. As the targets within the INS gene suffer from suboptimal specificity, we sought to improve the assay parameters by using the glucokinase gene (GCK) tissue-specific pancreatic promoter. The amount of methylated and unmethylated GCK DNA was measured using a droplet polymerase chain reaction assay and compared with the previously published INS-targeted assay. The method was tested using synthetic target sequences and DNA from pancreatic islets, blood, brain, kidney, large intestine, liver, lung, small intestine, and stomach. Circulating serum DNA was obtained from children with recent-onset type 1 diabetes (T1D) (n = 25), autoantibody-positive first-degree relatives of T1D patients (n = 14), and healthy controls (n = 20). The unmethylated GCK DNA was found to be more islet specific than unmethylated INS DNA. The proportion of the unmethylated GCK DNA was lower than INS in all tested extrapancreatic tissues, except kidney. Although the amounts of methylated DNA measured by the two assays were similar, the INS assay detected considerably more unmethylated DNA. Whereas none of the assays showed significant increase in the amount of unmethylated DNA, the ratio of unmethylated/methylated GCK DNA was borderline significantly increased in autoantibodypositive relatives compared with T1D patients (P = 0.04) and controls (P = 0.06). Targeting the assay into the GCK gene improved analytical parameters of the assay. As the amount of unmethylated target DNA in properly treated samples is very low, the clinical utility of this method remains to be evaluated.
T he autoimmune process, which leads to b cell destruction, usually begins several years prior to the onset of type 1 diabetes (T1D). Presently, better biomarkers to assess the ongoing process are needed, as autoantibodies (ABs) do not correctly reflect the stage, dynamics, or pace of b cell destruction, and other tools as metabolic markers come too late and are only indirect.
Recently, assessment of b cell death by the detection of specifically unmethylated DNA sequences originating from b cells in peripheral blood has been used by several groups both in animal models and humans (1) (2) (3) (4) (5) (6) . Generally, DNA methylation on cytosine-guanine dinucleotide (CpG) is a way of gene expression regulation. Gene promoters are usually unmethylated in cells or tissues where the gene is highly expressed and methylated in tissues where the gene is silenced. During the b cell's destruction, a small amount of b cell DNA is released from the islets into the circulation. If this circulating free DNA (cfDNA) in plasma or serum could be detectable, it would markedly improve our knowledge about the course of autoimmune process.
As insulin is substantially expressed only in b cells, previously proposed assays were detecting the circulating unmethylated insulin gene (INS). The INS promoter seemed to be a suitable target, but it contains repeating sequences (variable number of tandem repeats), which hamper the design of a specific polymerase chain reaction (PCR). To avoid a variable number of tandem repeats, some groups have targeted exon 2 of the INS gene. In exon 2, however, the CpGs unmethylated in b cells have been shown to be substantially unmethylated also in other tissues (e.g., in blood, breast, and liver) (4) . Unmethylated INS DNA from blood can particularly interfere with the assay, because the extraction of cfDNA is liable to contamination with DNA from blood cells.
We therefore sought to improve the analytic parameters by replacing this target with another sequence specifically unmethylated in b cells. The glucokinase gene (GCK) has two distinct promoters. The neuroendocrine promoter is active in b cells, glucose-sensitive neurons in the hypothalamus, and some enteroendocrine cells, whereas the hepatic promoter is active in liver (7) .
In this article, we report an assay targeted into the neuroendocrine promoter of GCK assessing the quantity of methylated and unmethylated cfDNA. The unique assay performance was compared with the previously published INS-targeted assay. Both assays were tested using synthetic methylated and unmethylated target DNA, DNA extracted from b cells, blood, brain, kidney, large intestine, liver, lung, small intestine, and stomach and on cfDNA from recent-onset T1D children, ABpositive first-degree relatives of T1D patients, and healthy controls.
Methods
To investigate the suitability of neuroendocrine GCK promoter as an assay target, we sequenced the promoter in blood cells and pancreatic islets specifically by methylation. The newly designed assay was first tested using a synthetic methylated and unmethylated target sequence and DNA extracted from pancreatic islets and a panel of extrapancreatic tissues (blood, brain, kidney, large intestine, liver, lung, small intestine, and stomach). Then we proceeded to the testing of cfDNA samples.
Study subjects
Three groups of subjects were included in the study: (1) Children with recent-onset T1D within 4 weeks after the diagnosis were recruited from our Center for Pediatric Diabetes (n = 25). (2) First-degree relatives of T1D patients (n = 14) were recruited from the PREDIA.CZ nationwide T1D prediction program (8) . Only those were included who tested positively for at least one AB within the past 6 months before the study sampling (9 of 14 children were positive for GAD65, 2 of 14 for insulin, 6 of 14 for insulinoma antigen 2, and 0 of 14 for zinc transporter 8 ABs). (3) Age-matched heathy controls (n = 20). The characteristics of the subjects are described in Table 1 . For the purpose of tissue-specific methylation analysis, we pooled whole blood DNA of several subjects from all three groups. Parents or legal guardians of the subjects consented in writing. The use of human samples has been approved by the institutional Ethics Committee.
AB measurement
ABs against insulin were measured using a radioimmunoassay from Medipan GMBH (Berlin, Germany). GAD65 and insulinoma antigen 2 ABs were measured using a radioimmunoassay purchased from RSR Ltd (Cardiff, United Kingdom). zinc transporter 8 ABs were measured using an enzyme-linked immunosorbent assay (RSR).
Methylation-specific sequencing of GCK promoter
The methylation degree of target sequence was verified by bisulphite sequencing of DNA from blood cells and pancreatic islets. After bisulphite conversion, the pancreatic promoter sequence of GCK was amplified from DNA extracted from pancreatic islets and from peripheral blood using GCKM2 primers (forward: 5 0 -GGTTAGTTTTGTTGAGGTTATTTTTGG-3 0 ; reverse: 5 0 -TCCTCTCCCTTCTATAACCTAAAAACA-3 0 ). PCR products were purified by the CleanPCR system (CleanNA, Alphen aan den Rijn, The Netherlands) and cloned into TOPO TA vector (Invitrogen, Carlsbad, CA). The cloning reaction was transformed into TOP10 cells (Invitrogen). Colonies containing target sequence were analyzed by direct sequencing. The target sequence was amplified using GCKM2 primers. The PCR products were purified by the Agencourt Ampure system (Beckman Coulter, Fullerton, California) and sequenced using BigDye Terminator 3.1 chemistry (Applied Biosystems, Warrington, United Kingdom), and sequencing products were purified by the Agencourt CleanSeq system (Beckman Coulter). Reactions were analyzed on the DNA sequencer ABI Prism 3130xl (Applied Biosystems) and inspected using the Sequence Scanner v1.0. 
Methylation-specific quantitative PCR
The level of unmethylated and methylated DNA was measured by dual fluorescent probe-based droplet digital PCR (ddPCR). The unique GCK assay was compared with an assay targeted to position -69 CpG of the insulin gene promoter, published earlier by Fisher et al. (2) (referred to as INS assay). We targeted our GCK assay into the neuroendocrine (pancreatic) promoter of the glucokinase gene (National Center for Biotechnology Information reference sequence: NG_008847.1) (referred to as GCK assay). The assay used 600 mM primers 5 0 -AGGARTATAGTAAGTTTTGGTAGGAGA-3 0 (forward) and 5 0 -TCTCACATCCTAACCTACTTCCCT-3 0 (reverse) and 150 mM probes, one for the methylated variant 5 0 -VIC-AACGCCGCTC-GACAT-3 0 (minor groove binder) and the other for the unmethylated variant 5 0 -FAM-AACACCACTCAACAT-3 0 (minor groove binder). The ddPCR reaction was performed using 90% ddPCR Supermix for probes (Bio-Rad, Hercules, CA) blended with 10% Qiagen HotStarTaq DNA polymerase with HotStar PCR buffer (Qiagen, Hilden, Germany). Cycling conditions were: 95°C for 10 min, followed by 40 cycles of 94°C for 30 seconds and 56.5°C for 1 minute and final denaturation at 98°C for 10 minutes. Samples were analyzed by the ddPCR QX100 droplet reader and Quanta-Soft software (Bio-Rad).
Synthetic plasmids for assay validation
Plasmids containing fully methylated and fully unmethylated sequence of (1) neuroendocrine GCK promoter sequence after bisulphite conversion and (2) INS promoter sequence after bisulphite conversion were purchased from Invitrogen (Carlsbad, CA). Plasmids were amplified in One Shot TOP10 chemically competent cells (Invitrogen) and purified using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO).
DNA extraction from tissue samples, pancreatic islets, and whole blood
A frozen tissue sample of brain, kidney, large intestine, liver, lung, small intestine, and stomach was obtained from an anonymous cadaveric donor. After thawing, samples were homogenized in a Bertin Minilys homogenizer using the Precellys Lysing Kit MK-28R (Bertin Corp., Rockville, MD). DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to the protocol for tissues. Pancreatic islets were purchased from Tebu-Bio (Le Perray-en-Yvelines, France). Upon arrival, islets were pelleted and stored at -80°C. Islet DNA was extracted using the Blood Mini Kit (Qiagen) according to the manufacturer's protocol for DNA extraction from cells. DNA from human blood was also extracted using the Qiagen Blood Mini Kit.
Serum processing
Peripheral blood was collected into Vacuette Z serum clot activator tubes (Greiner Bio-One, Kremsmunster, Austria). Blood samples were not taken under fasting conditions. To eliminate contamination risk by DNA from blood cells, all blood samples were processed within 2 hours after collection. The coagulated sample was first centrifuged at 1000g for 10 minutes at 4°C. Serum was transferred into 1.5-mL Eppendorf DNA LoBind tubes (Hamburg, Germany). To eliminate any remaining blood cells, serum was centrifuged for another 10 minutes at 14,000g at room temperature. Serum was then collected into a new tube without disturbing the pellet and frozen at -80°C until processing.
Extraction of circulating cell-free DNA
Circulating cell-free DNA was extracted from 0.5 mL thawed serum using the Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's recommendations, except for a 1-hour preincubation at room temperature with proteinase K and lysis buffer prior to the recommended incubation at 60°C.
Bisulphite treatment
Bisulphite conversion was performed using the EZ DNA Methylation Gold Kit (Zymo Research, Irvine, CA) according to the manufacturer's instruction. Reaction input was 20 mL of cfDNA.
Statistics
The statistical analysis was performed using R version 2.15.2. Differences between groups were tested using a Tukey honest significant difference (HSD) test. Correlation analyses were tested using Spearman rank correlation test. A P value of ,0.05 was considered significant.
Results

GCK assay development and validation
The target amplicon for our ddPCR assay contains three consecutive CpG sites. Their methylation status in blood cells and in pancreatic islets was first verified by subcloning the PCR products from bisulphite converted DNA and sequencing the clones. Although the CpG sites in blood were found to be predominantly methylated (16 of 17 clones were methylated), the ones in DNA from islets showed a substantial degree of unmethylation (10 of 16 clones were unmethylated) (Fig. 1) .
We then designed a methylation-specific ddPCR assay with a pair of probes annealing to the methylated or unmethylated sequence. Assay properties were tested using two plasmids containing a sequence methylated/ unmethylated at all three CpG sites. Plasmids in a concentration 2.5 3 10 1 , 2.5 3 10 2 , 2.5 3 10 3 , and 2.5 3 10 4 copies/reaction were measured in various mutual ratios ( Fig. 2 ; Supplemental Figs. 1 and 2).
Comparison of GCK and INS assays using synthetic plasmids Analogous measurements were performed with methylated/ unmethylated INS promoter containing plasmids and the INS assay. Whereas the GCK assay did not detect any false-positive copies of unmethylated DNA even in the presence 10 4 copies of methylated GCK plasmid, the INS assay showed probe cross-reactivity at the concentrations of 10 3 and 10 4 copies of methylated DNA background (Fig. 2) . This property of the INS assay made it impossible to assess unmethylated gene quantities whenever the background methylated DNA exceeded 10 3 copies/well.
Methylation of the GCK and INS assays target sequences in various tissues DNA extracted from pancreatic islets, blood, brain, kidney, large intestine, liver, lung, small intestine, and stomach was analyzed by GCK and INS assays to investigate the degree of methylation in these tissues. In the islet DNA, the specific CpGs were predominantly unmethylated (89% in the GCK and 69% in the INS genes). In tissues other than islets, the target sequences were predominantly methylated. The GCK assay target shows higher proportion of methylation in all tissues except for the kidney. The degree of methylation is illustrated in Fig. 3 .
Comparison of the two assays in clinical samples
The amount of serum samples allowed us to analyze the circulating DNA using both of the assays in majority of the clinical samples but not in all of them. Both measurements were performed in 23 recent-onset T1D patients, 9 AB-positive relatives of T1D patients, and 20 healthy controls. The amount of methylated DNA was similar using the two assays (GCK assay: range, 7 to 2432; median, 139 copies/250 mL of sample; INS assay: range, 6 to 2829; median, 83 copies/250 mL of sample), but the INS assay detected higher amount of unmethylated DNA (GCK assay: range, 0 to 15; median, 2 copies/ 250 mL serum; INS assay: range, 1.3 to 225; median, 14 copies/250 mL serum).
The correlation analysis between GCK and INS assays was performed using Spearman rank correlation test. The amount of unmethylated GCK DNA positively correlated with the amount of unmethylated INS DNA (P , 10 -4
). The correlation between the amount of methylated GCK and INS DNA was even stronger (P , 10 -9
). Surprisingly, the unmethylated/methylated DNA ratio did not correlate (P = 0.2).
We also tested the correlation between unmethylated and methylated DNA measured by the same assay (Spearman rank correlation test). There was a strong positive correlation between the amount of unmethylated and methylated DNA for both of the assays (GCK assay, P , 10 -6 ; INS assay, P , 10
). The correlation between methylated and unmethylated INS DNA was significant also when the different groups were analyzed separately (recent-onset T1D patients, P , 10 -14 ; controls, P , 10 -3 ;
and AB-positive relatives, P = 0.01). In the case of the GCK assay, the methylated and unmethylated DNA correlated only in the T1D (P , 10 -3 ) and control (P ,
10
-5 ) groups, but no correlation was apparent in ABpositive relatives (P = 0.6).
Differences in methylated and unmethylated DNA between study groups
The amount of unmethylated DNA was not increased in any of the studied groups using either GCK or INS assay [ Fig. 4(a) ]. The amount of methylated GCK DNA was increased in the recent-onset patients compared with the AB-positive relatives (Tukey HSD, P = 0.02), but no significant difference was found in the case of the INS assay [ Fig. 4(b) ]. When the unmethylated/methylated DNA ratio was applied, the two assays showed different results. The GCK assay detected a borderline significantly increased ratio in the group of AB-positive relatives compared with T1D children (Tukey HSD, P = 0.04) and controls (Tukey HSD, P = 0.06), whereas the INS assay showed an increased ratio in healthy controls compared with the T1D patients (Tukey HSD, P = 0.01) [Fig. 4(c) ].
Correlation of the amount of cfDNA with the clinical parameters
The correlation analysis with age was performed for all subjects together as well as separately for each group. There was no significant correlation between age and the amount of methylated and unmethylated GCK DNA or Figure 1 . A methylation status of GCK pancreatic promoter CpGs +13, +17, and +19. Target CpGs were predominantly unmethylated in islet DNA. Of 16 clones, 9 were fully unmethylated and 2 were partially unmethylated (60% unmethylated on average from 3 CpGs). Only 2 of 17 clones from blood DNA were partially unmethylated (94% methylated on average from 3 CpGs).
the GCK ratio. The absolute numbers of unmethylated and methylated INS DNA did not correlate with age either. The unmethylated/methylated INS ratio correlated with age when all groups were considered together (Spearman rank correlation test; P = 0.01, rho = 0.35; Supplemental Fig. 3 ) but not when each group was tested separately. This might be due to the fact that the control group, which has an increased INS ratio, is composed of slightly older children compared with other groups (Table 1) .
Furthermore, in recent-onset T1D patients, the cfDNA was also analyzed for correlation with body mass index (BMI), hemoglobin A1c (HbA1c), random C-peptide, and ABs at disease onset. The only association we observed was a negative correlation between the amount of methylated INS DNA and C-peptide (Spearman rank correlation test; P = 0.03, rho = -0.46; Supplemental Fig. 4 ). In the group of AB-positive relatives, the cfDNA was analyzed for correlation with BMI, HbA1c, and ABs. No significant correlation was detected.
Discussion
A reliable direct marker of ongoing autoimmune destruction of the b cell mass would be a valuable tool to study pathogenesis of T1D, to detect individuals at high risk of developing the disease, and to design prevention trials. However, such a marker is still lacking. Other research groups have recently designed assays assessing the pace of b cell death by detecting the unmethylated INS gene in the circulation. In this article, we introduce testing of the GCK gene to improve the performance metrics of the assessment. The ability of an assay to detect b cell death depends on at least three factors: (1) the selection of the assay target that is abundantly unmethylated in b cells in contrast to other tissues; (2) the power of the assay to sharply discriminate between the methylated and unmethylated sequence; and (3) a careful treatment of the primary sample aimed to avoid DNA contamination originating from cells decaying during the sample storage or processing.
Selection of assay target-comparison of the GCK and the INS assay performance
Because the total b cell mass in the body is relatively small compared with other tissues that contribute to the cfDNA pool, the specificity of unmethylation in the b cells is an important concern. The exon 2 +401 and +404 CpGs targeted by ddPCR assay used by Herold et al. (3) and Usmani-Brown et al. (6) were found to be about 70% unmethylated in blood, breast, and liver tissue (4). Unmethylated INS DNA from blood can particularly contribute to the total unmethylated signal, because the extraction of cfDNA is liable to contamination with DNA from blood cells. The INS promoter seems to be more specific than exon 2 (4).
In this article, we compared the methylation pattern of INS and GCK assay targets in various tissues. The GCK assay target shows higher proportion of methylation in all extrapancreatic tissues except for the kidney. The extent of contribution of the different tissues to the circulating DNA pool is not known, but the overall rate of unmethylation seemed lower in the GCK. Specifically, the proportion of unmethylated GCK DNA in blood was very low (99.6% by GCK assay, 1 out of 17 subclones by bisulphite sequencing), which is a notable improvement compared with other targets currently in use.
Discrimination between methylated and unmethylated sequence
In comparison with the earlier published ddPCR assays using methylation-specific probes (2, 6) the advantage of our GCK assay is that the probes cover three consecutive CpGs, and therefore there is a three-nucleotide difference between methylated and unmethylated probe. In the case of the INS assay, the target sequence contains only one CpG, which makes it more liable to nonspecific probe binding. Indeed, when we adopted the INS assay, we observed substantial cross-reactivity of the probes. This may be of high importance in the clinical setting.
Processing of the primary sample to avoid contamination by cellular DNA
The potential amount of target b cell-derived DNA is very small compared with the background DNA derived from all other sources. The major source of background DNA in sampled blood is probably blood cells, which might be damaged during blood drawing, centrifugation, and plasma/serum separation.
Delay in blood processing can lead to leukocyte apoptosis and release of the contaminating cellular DNA. Current literature is inconsistent in what the safe period of plasma/serum storage is. Reports have shown significant increase of cfDNA after 2 hours of storage compared with the baseline level (9), whereas others have reported no significant change up to 24 hours (10) . It is also important to clear the plasma/ serum of the remaining cells, which can be achieved by an additional centrifugation step or a filtration with a 0.2 mm filter after the serum/plasma collection (11) . We decided to prevent contamination by processing the blood within 2 hours after drawing and by adding an additional centrifugation step after the serum collection.
GCK and INS assay performance in the clinical samples
The majority of samples was analyzed using both GCK and INS assays. Although we observed a strong positive correlation between the assays in the amount of methylated and unmethylated DNA, the performance of the assays differed. Although the amounts of methylated DNA measured by the two assays seemed similar, the INS assay was detecting considerably higher amounts of unmethylated DNA. One explanation might be that the unmethylated INS DNA does not originate from the b cells, but rather from other sources, as the overall methylation in the tissues is lower in the INS assay target. The other possibility might be the false-positive unmethylation signal in the presence of a high background of methylated DNA, which we detected during the in vitro testing of the assays.
The drawbacks of detecting b cell-specific unmethylated DNA Our experience with measuring b cell-specific unmethylated DNA shows at least three major concerns undermining this approach.
Our data showed a striking difference in the unmethylated/methylated DNA ratio detected by GCK and INS assays. This discrepancy could be explained by the INS assay's incapability to accurately detect unmethylated DNA in the presence of a high background of methylated DNA (as discussed earlier) in combination with the fact that the amount of unmethylated GCK DNA in the samples is very low (0 to 15 copies/250 mL of serum). The accuracy of detection of such low amounts of DNA is suboptimal. A larger amount of serum sample would be needed to improve the reliability of detection.
There is a disagreement between different studies in terms of reporting the amount of target unmethylated DNA. Whereas Fisher et al. (2, 6) . In our opinion, it is important to adjust for the total amount of circulating DNA in the sample by using the ratio, because the unmethylated DNA does not originate exclusively from b cells. The discrepancy in the unmethylated/methylated ratio measured by GCK and INS assays shows the lack of robustness of this approach to measure b cell death.
Instability of the methylation pattern might also contribute to the discrepancy between different assays. Although relative stability of methylation in time and under disease conditions is assumed by this method, it has not been addressed specifically. The literature investigating Figure 3 . Comparison of (a) GCK and (b) INS assay discrimination between DNA from islets and other tissues. The degree of methylation of DNA from islets, blood, brain, kidney, large intestine, liver, lung, small intestine, and stomach was measured by GCK and INS assays. The proportion of unmethylated DNA in islets was higher in the GCK assay target (89.1%) compared with the INS assay target (68.4%). Using the GCK assay, the proportion of methylated DNA was higher in all other tissues except for the kidney DNA.
methylation of the GCK gene under diabetic conditions covers mainly methylation pattern in the blood cells, and data on methylation in pancreatic islets are scarce. However, a whole-genome methylation study performed on pancreatic islets from patients with type 2 diabetes (T2D) and healthy controls does not suggest .5% differences in the GCK or INS gene methylation between T2D and healthy donors (12) . Another study focusing specifically on the INS promoter shows increased methylation at CpGs -234, -180, -102, and +63 in pancreatic islets from T2D patients compared with controls but not at the -69 CpG site targeted by the INS assay (13). Another problem might be the strong correlation between the amount of methylated and unmethylated DNA using GCK assay and even stronger using the INS assay (P , 10 26 and P , 10 214 , respectively). This observation raises question whether the unmethylated DNA originates from the same source as the methylated DNA rather than from the b cells, because the methylation of the target outside b cells is never 100%. The pilot testing on clinical samples suggests that other more specific targets are still needed. A combination of markers might increase the specificity of the method to reveal the ongoing b cell destruction.
To detect a truly b cell-derived DNA, a larger sample volume than currently used might be needed. The GCK assay shows improvement in analytic parameters and specific unmethylation of the assay target compared to INS gene. We have also taken strict precautions to avoid contamination by cellular DNA during sample processing. Nevertheless, we failed to reliably detect the increased unmethylated DNA in the amount of serum even higher than the amount used by other groups [we used 500 mL of serum; Fisher et al. (2) describes using 30 to 50 mL, and 200 mL of serum was used by Herold et al. 
Conclusion
Although the methylation pattern of the GCK assay target seems to be more specific and the newly developed ddPCR assay shows improved analytical parameters, the clinical utility of the assay is still unsatisfactory. The direct comparison with the INS-targeted assay raises important questions about the origin of the unmethylated DNA detected by this approach. In our opinion, the detection of truly b cell-derived DNA requires a larger amount of serum than presently used, appropriate processing of the blood sample, and employment of more specific markers.
